1 comprises a clinically and genetically heterogeneous group of heritable connective tissue disorders characterized by ocular, auditory, skeletal and orofacial abnormalities. 2 Its incidence among neonates is~1 in 7,500-9,000. The typical mode of inheritance is autosomal dominant; heterozygous mutations in COL2A1 (OMIM# 120140), COL11A1 (OMIM# 120280) and COL11A2 (OMIM# 120290) cause Stickler syndrome types 1 (OMIM# 108300), 2 (OMIM# 604841) and 3 (OMIM# 184840), respectively. [3] [4] [5] The differential diagnosis is made according to the patient's clinical characteristics, but may sometimes be difficult because of the phenotypic variability. The diagnosis can be confirmed using molecular genetic analysis.
Standard Sanger sequencing, which is routinely used to identify pathogenic mutations, is laborious, expensive and time consuming, particularly when applied to the analysis of large genes, including those coding collagens, with numerous exons and for multiple genes that are possibly responsible for genetic diseases. Targeted next-generation sequencing (NGS) of candidate and/or known pathogenic genes can be used to overcome problems associated with Sanger sequencing to diagnose patients with disorders, including Stickler syndrome. 6 We report the use of targeted NGS to study a Japanese patient with Stickler syndrome and the identification of a novel heterozygous COL11A1 intronic mutation outside of the highly conserved AG-GT dinucleotides, NM_001854.3:c.3168+5G4A. The mutation was present in a targeted exome panel comprising the coding regions of 4,813 clinical phenotype-associated genes, including Stickler syndromerelated genes. The functionally significant effects of this mutation on the splice donor site were revealed through in silico analysis and functional experiments using a minigene assay, and suggested that this mutation was the cause of Stickler syndrome in this patient.
The subject was a 4-year-old girl. She was born to healthy nonconsanguineous Japanese parents after 38 weeks of gestation. The ethics committees of Tokushima University approved this study. After obtaining informed consent from her parents, a molecular diagnosis was performed using genomic DNA extracted from the patient's whole blood. Because several genes with numerous exons cause Stickler syndrome or related diseases, we first used a MiSeq benchtop sequencer (Illumina, San Diego, CA, USA) to perform NGS with a TruSight One Sequencing Panel (Illumina). The alignments of sequencing reads to the human reference genome (hg19), duplicate read removal, local realignment around indels, base quality score recalibration, variant calling and annotation were performed as described elsewhere. 7 To identify single-nucleotide variations, we excluded sequence variants with minor allele frequencies 40.05 included in the 1,000 Genomes Project database (http://www.1000 genomes.org/), NHLBI GO Exome Sequencing Project (ESP6500, http://evs.gs. washington.edu/EVS/) and Human Genetic Variation Database (HGVD, http://www.genome.med.kyoto-u.ac.jp/SnpDB/). Detection of copy-number alteration using NGS data with a resolution of a single exon to several exons depending on the exon size was performed as described elsewhere. 7 These analyses identified one heterozygous mutation, NM_001854.3:c.3168+5G4A (NC_000001.10:g.103427417C4T), within an intronic sequence (intron 41) of COL11A1 (NM_001854.3; Figure 2a ). No other potentially pathogenic mutations, including variants and gross deletions, were detected in genes potentially responsible for Stickler syndrome or related diseases. This mutation is evolutionarily conserved in mammals, chickens and zebrafish (Supplementary Figure S1) and is not present in dbSNP138, 1000 Genomes Project, ESP6500 or HGVD. Although 25 point mutations, including 4 at the +3 position and 4 at the +5 position and 1 small insertion of the 73 mutations were listed as mutations located within the flanking intronic sequences that possibly affect normal splicing in Human Gene Mutation Database Professional 2015.2 (HGMD, http://www.hgmd.org/), this mutation is not present in HGMD and ClinVar (http://www.ncbi. nlm.nih.gov/clinvar/), suggesting that it is a novel mutation responsible for Stickler syndrome. Because parental DNA was not available, the mutation was not confirmed as occurring de novo.
To evaluate the pathogenicity of this mutation, we used several in silico splice site prediction programs, such as Alternative Splice Site Predictor (http://wangcomputing.com/assp/), NetGene2 (http://www.cbs.dtu.dk/services/NetGene2/), NNSPLICE 0.9 (http://www.fruitfly.org/seq_tools/splice.html), Human Splice Finder3 (http://www.umd.be/HSF/) and MaxEnt Scan (http://genes. mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html). These analyses predicted that the change weakened the donor spliced site (Figure 2b ). The scores calculated using Alternative Splice Site Predictor, NetGene2, NNSPLICE 0.9, Human Splicing Finder3 and MaxEntScan are displayed below each splice site. A higher score predicts a strong splice site. Note that the scores of a splice donor site of exon 41 were markedly decreased by the c.3168+5G4A mutation determined using most of the prediction tools. (c) Left, diagrams of exon 41 and parts of flanking introns 40 and 41, the location of the c.3168+5G4A mutation (left upper) and the pET01 construct (left lower). In the pET01 construct, the intron containing the multiple cloning site (MCS) is flanked by the 5ʹ-donor and 3ʹ-acceptor splice sites of pre-proinsulin 5ʹ and 3ʹ exons, respectively (http://www.mobitec.com/cms/products/bio/04_vector_sys/exontrap.html). The expression of this vector sequence was driven by the promoter present in the long terminal repeat (LTR) of Rous Sarcoma Virus followed by a short stretch of a eukaryotic gene (phosphatase). The sequences containing the mutation detected in COL11A1 intron 41 (MUT) or those that did not (WT) were cloned into the MCS of pET01. The primers used in the reverse transcription-PCR (RT-PCR) experiments within the preproinsulin 5ʹ and 3ʹ exons are indicated by the arrows (Supplementary Table S1 ). The length of each fragment is indicated. Right, representative results of RT-PCR analysis using HCT116 and HEK293 cells transfected with an empty pET01 vector (mock), the pET01-WT containing the WT fragment or the pET01-MUT vector containing the MUT fragment. The 301-bp transcript, including COL11A1 exon 41 (54-bp), was detected in cells transfected with pET01-WT, whereas the 247-bp transcript without this exon was detected in mock-and pET01-MUT-transfected cells. Each transcript is indicated to the right of the gel. The asterisks indicate nonspecific bands. (d) Nucleotide and amino acid sequences of transcripts obtained in the minigene assay. A closed arrow denotes the sequence from COL11A1 exon 41, and arrows denote the sequence of the preproinsulin 5ʹ and 3ʹ exons. Sequence analysis did not detect a 54-bp exonic sequence in the transcripts present in pET01-MUT-transfected cells, suggesting that the c.3168+5G4A mutation inactivated the splice donor site of COL11A1 exon 41.
To validate these predictions, we used a functional assay that may be useful for diagnostic laboratories to quickly examine the potential pathogenic effects of sequence variants. A minigene assay was performed to determine the effect of the mutation on COL11A1 transcript splicing. 8 A 1,678-bp genomic DNA fragment that included COL11A1 exon 41 and its flanking sequences (parts of introns 40 and 41) was amplified by PCR with primers containing the appropriate restriction enzyme sites (Supplementary Table S1 ) from the patient carrying the wild-type and variant (mutated) alleles. PCR products were cloned into the Exontrap Cloning Vector pET01 (MoBiTec GmbH, Göttingen, Germany; Figure 2c) ; their sequences were validated using Sanger sequencing.
Because intron 41 is 410 kb, we included a part of intron 41 (1,533 bp) that may contain several cryptic splice donor sites instead of the correct donor site predicted in silico in the fragment used for the minigene assay. The wild-type and mutant transcripts were produced by transient transfection of empty (pET01-mock), Novel COL11A1 mutation in Stickler syndrome T Kohmoto et al wild-type (pET01-WT) or mutant (pET01-MUT) plasmids into HCT116 or HEK293 cells using FuGENE6 (Promega, Madison, WI, USA) according to the manufacturer's instructions. Total RNA obtained from cells 48 h after transfection was subjected to reverse transcription-PCR (RT-PCR) using primers corresponding to the 5ʹ and 3ʹ exons in the pET01 vector (Supplementary Table S1 ). The cells that were transfected with pET01-WT produced a 301-bp band that was consistent with correct mRNA splicing (Figure 2c ). In contrast, RT-PCR analysis detected a 247-bp band in cells that were transfected with pET01-MUT containing the c.3168+5G4A mutation (Figure 2c ) and in cells that were transfected with the empty vector (mock). Direct sequencing of the RT-PCR products revealed that the larger fragments were observed in cells that were transfected with pET01-WT containing an insertion of 54 bp of exon 41 because of normal splicing and that cells transfected with pET01-MUT lacked this insertion (Figure 2d ). These findings indicate that the c.3168+5G4A mutation disrupted the donor splice site of exon 41 and induced the skipping of the entire exon 41, encoding 18 amino acid residues. A similar result from a minigene assay has been reported from a Stickler syndrome case with a small insertion in the same intron 41 of COL11A1 (NM_001854.3:c.3168+2_3168+3insTT). 9, 10 Because only a part of intron 41 was tested in the minigene assay, we were unable to determine whether this mutation induced exon skipping, as observed in the minigene assay or activated a cryptic donor site somewhere within intron 41 to generate a larger aberrant exon. In either case, the c.3168+5G4A mutation likely affected mRNA processing and produced a misspliced transcript, although we were unable to determine whether an aberrant transcript was present in the patient's cells because COL11A1 is mainly expressed in mesenchymal cells. Cartilage and skin fibroblasts, which may express COL11A1 mRNA, were unavailable from the affected patient. 11, 12 The use of NGS in diagnostic laboratories will facilitate the characterization of a greater number of unclassified variants detected in patients with genetic disorders. For example, a significant number of non-exonic mutations may exist within candidate genes contributing to Stickler syndrome. 11 Significant portions of the reads obtained in whole or targeted exome sequencing from outside the targeted regions 13 or complete genome capture of target genes may enhance the detection of non-exonic variants with uncertain pathogenicity. Therefore, integrated analyses using databases, bioinformatics tools, and functional studies may be critical for determining the pathogenicity of variants and facilitating differential diagnosis, appropriate therapy, and genetic counseling for patients with Stickler syndrome and related diseases.
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